These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23565620)

  • 21. Directly acting antivirals against hepatitis C virus.
    Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
    J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New pharmacotherapy for hepatitis C.
    Assis DN; Lim JK
    Clin Pharmacol Ther; 2012 Sep; 92(3):294-305. PubMed ID: 22850602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice.
    Weiss JJ; Alcorn MC; Rabkin JG; Dieterich DT
    J Hepatol; 2012 Feb; 56(2):503-4. PubMed ID: 21718669
    [No Abstract]   [Full Text] [Related]  

  • 25. Telaprevir for chronic HCV infection.
    van der Meer AJ; de Knegt RJ
    N Engl J Med; 2009 Jul; 361(5):533-4; author reply 534-5. PubMed ID: 19641215
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Enea M; Bruno R; Bronte F; Capursi V; Cicchetti A; Colombo GL; Di Marco V; Gasbarrini A; Craxì A;
    Hepatology; 2012 Sep; 56(3):850-60. PubMed ID: 22454336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clearance duration as a predictor of sustained viral response in patients with chronic hepatitis C virus genotype 1.
    Shenoy M; Levin J; Said A; Striker R
    J Infect Dis; 2005 Jun; 191(11):1993-5; 1995-6. PubMed ID: 15871137
    [No Abstract]   [Full Text] [Related]  

  • 28. Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis.
    el-Khattib AA; Abdelhakam SM; Ghoraba DM; Ibrahim WA; Sayed MM
    Eur J Intern Med; 2012 Jan; 23(1):e34-5. PubMed ID: 22153547
    [No Abstract]   [Full Text] [Related]  

  • 29. [Similar poor response in genotype 4 chronic Hepatitis C treatment with interferon and ribavirin compared with genotype 1 treatment].
    Pérez Mota A; Graus J; García Flores MA; Blanco M; Pérez-Muñoz C; Villalgordo C; Rodero R
    Rev Esp Enferm Dig; 2003 Mar; 95(3):238-9. PubMed ID: 12760714
    [No Abstract]   [Full Text] [Related]  

  • 30. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing Prevalence of Untypable and Mixed Genotypes of Hepatitis C Virus in Pakistan: Latest Trends in 2018.
    Wahid B; Naeem N; Altaf S; Ilyas N
    Viral Immunol; 2019 May; 32(4):192-194. PubMed ID: 30939104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral agents and hepatitis C.
    Archer-Festa M; Nilsen-Kupsch S
    N Y State Dent J; 2012; 78(4):42-5. PubMed ID: 23252194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Studies with boceprevir].
    MMW Fortschr Med; 2011 Jul; 153(29-31):16. PubMed ID: 21830728
    [No Abstract]   [Full Text] [Related]  

  • 35. [Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].
    Nikitin IG; Gogova LM; Baikova IE; Kislyakov VA; Volynkina VM
    Ter Arkh; 2012; 84(11):75-80. PubMed ID: 23252254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approach to the treatment-naïve patient with HCV genotype 1 infection.
    Muir AJ
    Infect Dis Clin North Am; 2012 Dec; 26(4):893-901. PubMed ID: 23083822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recommendations for the treatment of chronic genotype 1 hepatitis C virus infection].
    Silva MO; Ridruejo E; Galdame O; Bessone F; Colombato L; Daruich J; Fainboim H; Fassio E; Fay F; Frider B; Gadano A; Galoppo MC; González J; Tanno H; Terg R; Villamil F; ;
    Acta Gastroenterol Latinoam; 2012 Sep; 42(3):234-49. PubMed ID: 23214356
    [No Abstract]   [Full Text] [Related]  

  • 39. NS5A inhibitors to treat hepatitis C virus infection.
    Welzel TM; Zeuzem S
    Lancet Infect Dis; 2012 Sep; 12(9):648-9. PubMed ID: 22714000
    [No Abstract]   [Full Text] [Related]  

  • 40. Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia.
    Kikvidze T; Luhmann N; Avril E; Butsashvili M; Labartkava K; Etienne A; Le Pluart D; Inaridze I; Gamezardashvili A; Kharshiladze D; Bouscaillou J
    Int J Drug Policy; 2018 Feb; 52():16-19. PubMed ID: 29227878
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.